A systematic analysis of commonly used antibodies in cancer diagnostics

Histopathology

Volumn 64, Issue 2, 2014, Pages 293-305

  Gremel, Gabriela ^a   Bergman, Julia ^a   Djureinovic, Dijana ^a   Edqvist, Per Henrik ^a   Maindad, Vikas ^b   Bharambe, Bhavana M ^b   Khan, Wasif Ali Z A ^b   Navani, Sanjay ^c   Elebro, Jacob ^d,e   Jirström, Karin ^d,e   Hellberg, Dan ^a   Uhlén, Mathias ^f   Micke, Patrick ^a   Pontén, Fredrik ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Department of Pathology Grant Government Medical College Sir Jamshedji Jeejeebhoy Group of Hospitals   (India)

^c Lab Surgpath   (India)

^d LUND UNIVERSITY   (Sweden)

^e Occupational and Environmental Medicine   (Sweden)

^f SCIENCE FOR LIFE LABORATORY   (Sweden)

Author keywords

Biological tumour markers; Differential diagnosis; Immunohistochemistry; Surgical pathology; Tissue microarray analysis

Indexed keywords

ANTIBODY; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN A; CYTOKERATIN; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 20; CYTOKERATIN 5; CYTOKERATIN 7; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; GROSS CYSTIC DISEASE FLUID PROTEIN 15; MAMMAGLOBIN; NAPSIN A; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN P63; PROTEIN S100B; SYNAPTOPHYSIN; THYROGLOBULIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; VILLIN; VIMENTIN; WILMS TUMOR 1 PROTEIN;

ADENOSQUAMOUS CARCINOMA; ARTICLE; BILE DUCT CARCINOMA; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER DIAGNOSIS; CLEAR CELL CARCINOMA; COLORECTAL CARCINOMA; DERMATOFIBROMA; DIFFERENTIAL DIAGNOSIS; EMBRYONAL CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GERM CELL TUMOR; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIVER CELL; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MELANOMA; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SEMINOMA; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STAINING; STOMACH ADENOCARCINOMA; THYROID CARCINOMA; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

BIOLOGICAL TUMOUR MARKERS; DIFFERENTIAL DIAGNOSIS; IMMUNOHISTOCHEMISTRY; SURGICAL PATHOLOGY; TISSUE MICROARRAY ANALYSIS;

ANTIBODIES; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84890154421     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12255     Document Type: Article

References (29)

1. Pavlidis N, Briasoulis E, Hainsworth J et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur. J. Cancer 2003; 39; 1990-2005.
2. Dennis JL, Hvidsten TR, Wit EC et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin. Cancer Res. 2005; 11; 3766-3772.
3. Park SY, Kim BH, Kim JH et al. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch. Pathol. Lab. Med. 2007; 131; 1561-1567.
4. Hashimoto K, Sasajima Y, Ando M et al. Immunohistochemical profile for unknown primary adenocarcinoma. PLoS ONE 2012; 7; e31181.
5. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 2005; 47; 231-247.
6. Shah AA, Frierson HF Jr, Cathro HP. Analysis of immunohistochemical stain usage in different pathology practice settings. Am. J. Clin. Pathol. 2012; 138; 831-836.
7. Bahrami A, Truong LD, Ro JY. Undifferentiated tumor: true identity by immunohistochemistry. Arch. Pathol. Lab. Med. 2008; 132; 326-348.
8. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology 2005; 47; 1-16.
9. Bejarano PA, Nikiforov YE, Swenson ES et al. Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. Appl. Immunohistochem. Mol. Morphol. 2000; 8; 189-194.
10. Kampf C, Olsson I, Ryberg U et al. Production of tissue microarrays, immunohistochemistry staining and digitalization within the Human Protein Atlas. J. Vis. Exp. 2012; 63; 3620.
11. Spitalnic S. Test properties I: sensitivity, specificity, and predictive values. Hosp. Physician 2004; 40; 27-31.
12. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002; 40; 403-439.
13. Balaton AJ, Nehama-Sibony M, Gotheil C et al. Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections. J. Pathol. 1988; 156; 305-310.
14. Kaufmann O, Fietze E, Mengs J et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am. J. Clin. Pathol. 2001; 116; 823-830.
15. Drlicek M, Bodenteich A, Urbanits S et al. Immunohistochemical panel of antibodies in the diagnosis of brain metastases of the unknown primary. Pathol. Res. Pract. 2004; 200; 727-734.
16. Payne SJ, Bowen RL, Jones JL et al. Predictive markers in breast cancer - the present. Histopathology 2008; 52; 82-90.
17. Turner BM, Cagle PT, Sainz IM et al. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch. Pathol. Lab. Med. 2012; 136; 163-171.
18. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum. Pathol. 2010; 41; 20-25.
19. Ye J, Findeis-Hosey JJ, Yang Q et al. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl. Immunohistochem. Mol. Morphol. 2011; 19; 313-317.
20. Zhang P, Han YP, Huang L et al. Value of napsin A and thyroid transcription factor-1 in the identification of primary lung adenocarcinoma. Oncol. Lett. 2010; 1; 899-903.
21. Bayrak R, Haltas H, Yenidunya S. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody. Diagn. Pathol. 2012; 7; 9.
22. Werling RW, Yaziji H, Bacchi CE et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am. J. Surg. Pathol. 2003; 27; 303-310.
23. Ponten F, Gry M, Fagerberg L et al. A global view of protein expression in human cells, tissues, and organs. Mol. Syst. Biol. 2009; 5; 337.
24. Brennan DJ, O'Connor DP, Rexhepaj E et al. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat. Rev. Cancer 2010; 10; 605-617.
25. Uhlen M, Ponten F. Antibody-based proteomics for human tissue profiling. Mol. Cell. Proteomics 2005; 4; 384-393.
26. Asplund A, Edqvist PH, Schwenk JM et al. Antibodies for profiling the human proteome - the Human Protein Atlas as a resource for cancer research. Proteomics 2012; 12; 2067-2077.
27. Uhlen M, Oksvold P, Fagerberg L et al. Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol. 2010; 28; 1248-1250.
28. Ponten F, Schwenk JM, Asplund A et al. The Human Protein Atlas as a proteomic resource for biomarker discovery. J. Intern. Med. 2011; 270; 428-446.
29. Magnusson K, de Wit M, Brennan DJ et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am. J. Surg. Pathol. 2011; 35; 937-948.